RU2016141449A3 - - Google Patents

Download PDF

Info

Publication number
RU2016141449A3
RU2016141449A3 RU2016141449A RU2016141449A RU2016141449A3 RU 2016141449 A3 RU2016141449 A3 RU 2016141449A3 RU 2016141449 A RU2016141449 A RU 2016141449A RU 2016141449 A RU2016141449 A RU 2016141449A RU 2016141449 A3 RU2016141449 A3 RU 2016141449A3
Authority
RU
Russia
Application number
RU2016141449A
Other languages
Russian (ru)
Other versions
RU2016141449A (ru
RU2694368C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016141449A publication Critical patent/RU2016141449A/ru
Publication of RU2016141449A3 publication Critical patent/RU2016141449A3/ru
Application granted granted Critical
Publication of RU2694368C2 publication Critical patent/RU2694368C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2016141449A 2014-03-31 2015-03-30 Твердые фармацевтические композиции, содержащие производные биоптерина, и способы применения таких композиций RU2694368C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14162727.3 2014-03-31
EP14162727.3A EP2926805B1 (en) 2014-03-31 2014-03-31 Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PCT/EP2015/056824 WO2015150294A1 (en) 2014-03-31 2015-03-30 Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions

Publications (3)

Publication Number Publication Date
RU2016141449A RU2016141449A (ru) 2018-05-07
RU2016141449A3 true RU2016141449A3 (cg-RX-API-DMAC7.html) 2018-12-14
RU2694368C2 RU2694368C2 (ru) 2019-07-12

Family

ID=50389975

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016141449A RU2694368C2 (ru) 2014-03-31 2015-03-30 Твердые фармацевтические композиции, содержащие производные биоптерина, и способы применения таких композиций

Country Status (28)

Country Link
US (6) US9895372B2 (cg-RX-API-DMAC7.html)
EP (2) EP2926805B1 (cg-RX-API-DMAC7.html)
JP (3) JP6552515B2 (cg-RX-API-DMAC7.html)
KR (1) KR102374500B1 (cg-RX-API-DMAC7.html)
CN (2) CN106572976A (cg-RX-API-DMAC7.html)
AU (2) AU2015239736B2 (cg-RX-API-DMAC7.html)
CA (1) CA2938267C (cg-RX-API-DMAC7.html)
CL (1) CL2016002463A1 (cg-RX-API-DMAC7.html)
CY (1) CY1117881T1 (cg-RX-API-DMAC7.html)
DK (1) DK2926805T3 (cg-RX-API-DMAC7.html)
ES (1) ES2586945T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160802T1 (cg-RX-API-DMAC7.html)
HU (1) HUE030221T2 (cg-RX-API-DMAC7.html)
IL (1) IL248090B (cg-RX-API-DMAC7.html)
MX (1) MX377919B (cg-RX-API-DMAC7.html)
MY (1) MY180844A (cg-RX-API-DMAC7.html)
PE (1) PE20161253A1 (cg-RX-API-DMAC7.html)
PH (1) PH12016501519B1 (cg-RX-API-DMAC7.html)
PL (1) PL2926805T3 (cg-RX-API-DMAC7.html)
PT (1) PT2926805T (cg-RX-API-DMAC7.html)
RS (1) RS54973B1 (cg-RX-API-DMAC7.html)
RU (1) RU2694368C2 (cg-RX-API-DMAC7.html)
SA (1) SA516371933B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201606151SA (cg-RX-API-DMAC7.html)
SI (1) SI2926805T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600246B (cg-RX-API-DMAC7.html)
WO (1) WO2015150294A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201605271B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6382997B2 (ja) 2014-02-07 2018-08-29 エクセセーラ ファーマシューティカルズ インコーポレイテッド 治療用化合物および組成物
PL2926805T3 (pl) 2014-03-31 2016-12-30 Stałe kompozycje farmaceutyczne zawierające pochodne biopteryny oraz zastosowania takich kompozycji
JP2016168783A (ja) * 2015-03-13 2016-09-23 株式会社東芝 記録装置、記録方法、及び記録媒体
US12171766B2 (en) 2021-12-03 2024-12-24 Verinos Operations Gmbh Methods of treating patients suffering from brain injury and methods of increasing the value of the extended Glasgow Outcome Scale of patients suffering from brain injury
BR112020003865A8 (pt) * 2017-09-01 2022-08-16 Censa Pharmaceuticals Inc Composições farmacêuticas compreendendo sepiapterina e seus usos
JP6565103B2 (ja) * 2017-09-06 2019-08-28 株式会社昭和冷凍プラント 香気成分含有水溶液を含む液状製品の製造方法
LT4034122T (lt) * 2019-09-25 2025-11-10 Hiperfenilalaninemijos gydymo būdai
WO2023099013A1 (en) 2021-12-03 2023-06-08 Verinos Operations Gmbh Methods of treating patients suffering from brain injury and methods of increasing the value of the extended glasgow outcome scale of patients suffering from brain injury
TW202406555A (zh) 2022-05-06 2024-02-16 德商veriNOS運營有限公司 治療患有與增加的麩胺酸水平相關的疾病狀況或病症的患者的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922713A (en) * 1997-06-26 1999-07-13 Werner; Ernst Inhibition of nitric oxide synthase
ATE201412T1 (de) 1997-10-06 2001-06-15 Ernst Werner Pteridinderivate als no synthase-hemmer
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
WO2005037286A1 (en) * 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia
ES2755334T3 (es) * 2003-11-17 2020-04-22 Merck & Cie Proceso para la preparación de formas cristalinas B de clorhidrato de (6R)-L-eritro-tetrahidrobiopterina a partir de otras formas cristalinas
DK1757293T3 (da) * 2004-05-11 2012-10-22 Daiichi Sankyo Co Ltd Bh4-responsiv hyperphenylalaninæmi-medikamenter
SE0401826D0 (sv) 2004-07-09 2004-07-09 Trimble Ab Method of preparing a winding for an n-phase motor
JP2008520574A (ja) * 2004-11-17 2008-06-19 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリンの安定性錠剤処方物
EP1669355A1 (en) * 2004-12-02 2006-06-14 Vasopharm Biotech GmbH Aminotetrahydropteridines and processes for manufacture thereof
AU2008240259C1 (en) * 2007-04-11 2022-11-24 Biomarin Pharmaceutical Inc. Tetrahydrobiopterin compositions and methods of measuring
EP2140731A2 (de) 2007-04-24 2010-01-06 Osram Gesellschaft mit Beschränkter Haftung Schaltungsanordnung zur zündung und zum betrieb einer entladungslampe
ES2736730T3 (es) 2008-08-12 2020-01-07 Orpha Swiss Gmbh Forma de administración farmacéutica que contiene tetrahidrobiopterina
KR20140021585A (ko) 2011-03-01 2014-02-20 루비콘 리서치 피브이티. 엘티디. 테트라하이드로바이옵테린의 안정한 조성물
WO2013033194A1 (en) * 2011-08-30 2013-03-07 Fresenius Kabi Usa, Llc Levothyroxine formulations
PL2926805T3 (pl) * 2014-03-31 2016-12-30 Stałe kompozycje farmaceutyczne zawierające pochodne biopteryny oraz zastosowania takich kompozycji

Also Published As

Publication number Publication date
PH12016501519A1 (en) 2017-02-06
BR112016020101A2 (cg-RX-API-DMAC7.html) 2017-07-15
CA2938267C (en) 2023-05-09
WO2015150294A1 (en) 2015-10-08
CN106572976A (zh) 2017-04-19
US9895372B2 (en) 2018-02-20
AU2015239736A1 (en) 2016-08-11
AU2020203880B2 (en) 2022-03-31
JP7178731B2 (ja) 2022-11-28
EP2926805B1 (en) 2016-05-18
SG11201606151SA (en) 2016-08-30
SA516371933B1 (ar) 2019-04-14
JP2021105062A (ja) 2021-07-26
RS54973B1 (sr) 2016-11-30
PL2926805T3 (pl) 2016-12-30
MX377919B (es) 2025-03-10
CN113521017A (zh) 2021-10-22
PE20161253A1 (es) 2016-11-13
US20220031703A9 (en) 2022-02-03
US12458644B2 (en) 2025-11-04
US10016431B2 (en) 2018-07-10
US20170112836A1 (en) 2017-04-27
CL2016002463A1 (es) 2017-01-27
RU2016141449A (ru) 2018-05-07
BR112016020101A8 (pt) 2021-06-29
HRP20160802T1 (hr) 2016-08-12
ZA201605271B (en) 2017-08-30
HUE030221T2 (en) 2017-04-28
US10493075B2 (en) 2019-12-03
AU2015239736B2 (en) 2020-03-26
US20200046710A1 (en) 2020-02-13
US20210137927A1 (en) 2021-05-13
AU2020203880A1 (en) 2020-07-02
ES2586945T3 (es) 2016-10-19
EP2926805A1 (en) 2015-10-07
JP2017509623A (ja) 2017-04-06
MX2016012784A (es) 2017-04-25
US20180289714A1 (en) 2018-10-11
CY1117881T1 (el) 2018-03-07
PH12016501519B1 (en) 2017-02-06
IL248090A0 (en) 2016-11-30
JP6879582B2 (ja) 2021-06-02
CA2938267A1 (en) 2015-10-08
KR102374500B1 (ko) 2022-03-15
JP2019194227A (ja) 2019-11-07
US20170296543A1 (en) 2017-10-19
DK2926805T3 (en) 2016-07-25
PT2926805T (pt) 2016-07-15
JP6552515B2 (ja) 2019-07-31
SI2926805T1 (sl) 2016-09-30
RU2694368C2 (ru) 2019-07-12
US10925877B2 (en) 2021-02-23
SMT201600246B (it) 2016-08-31
EP3125864A1 (en) 2017-02-08
IL248090B (en) 2019-10-31
HK1213195A1 (en) 2016-06-30
NZ722455A (en) 2022-03-25
KR20160138406A (ko) 2016-12-05
MY180844A (en) 2020-12-10
US20230355630A1 (en) 2023-11-09
US11717522B2 (en) 2023-08-08

Similar Documents

Publication Publication Date Title
BR112016018076A2 (cg-RX-API-DMAC7.html)
BR112016016951A2 (cg-RX-API-DMAC7.html)
BR112016018238A2 (cg-RX-API-DMAC7.html)
BR112016017303A2 (cg-RX-API-DMAC7.html)
BR112016016741A2 (cg-RX-API-DMAC7.html)
BR112016018369A2 (cg-RX-API-DMAC7.html)
BR112016017657A2 (cg-RX-API-DMAC7.html)
BR112016016451A2 (cg-RX-API-DMAC7.html)
BR112016017137A2 (cg-RX-API-DMAC7.html)
BR112016016751A2 (cg-RX-API-DMAC7.html)
BR112016018575A2 (cg-RX-API-DMAC7.html)
BR112016018705A2 (cg-RX-API-DMAC7.html)
BR112016016992A2 (cg-RX-API-DMAC7.html)
BR112016016268A2 (cg-RX-API-DMAC7.html)
BR112016016944A2 (cg-RX-API-DMAC7.html)
BR112016017216A2 (cg-RX-API-DMAC7.html)
BR112016016537A2 (cg-RX-API-DMAC7.html)
BR112016019754A2 (cg-RX-API-DMAC7.html)
RU2016141449A3 (cg-RX-API-DMAC7.html)
BR112016017679A2 (cg-RX-API-DMAC7.html)
BR112016017130A2 (cg-RX-API-DMAC7.html)
BR112016018749A2 (cg-RX-API-DMAC7.html)
BR112016017542A2 (cg-RX-API-DMAC7.html)
BR112016017752A2 (cg-RX-API-DMAC7.html)
BR112016017513A2 (cg-RX-API-DMAC7.html)